Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXB-102 (AXO-Lenti-PD) in Advanced Parkinson's Disease
NCT03720418Phase 2Terminated
- Sponsor
- Sio Gene Therapies
- Start
- Oct 2018
- Primary completion
- Apr 2022
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of OXB-102 in Parkinson's disease (PD), sponsored by Sio Gene Therapies. Started Oct 2018; status: terminated.
02
Drugs
OXB-102
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03720418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720418.